Cervical screening looks for high-risk HPV or changes in cervical cells so that people who need follow-up can receive it. An abnormal screening result often concerns infection or precancerous changes. The next step depends on the exact result and earlier history, so keep the report and the follow-up plan together.
Know which test was done
The NCI screening explanation distinguishes an HPV test, which checks for high-risk virus types, from a Pap test, which examines cervical cells for changes. Co-testing combines both. Biopsy examines tissue when diagnosis or assessment of a lesion is needed.
Most HPV infections resolve, while persistent infection with certain high-risk types can lead to precancer and cancer. A positive HPV result can also appear after years of negative tests because a previous infection may become active again. The result alone cannot establish when the infection began or identify a partner as its source.
New bleeding after sex, between periods or after menopause, or unusual discharge or pelvic pain, deserves clinical assessment. A routine screening schedule is for people without symptoms; tell the service about symptoms when booking.
For questions involving the ovaries, the separate ovarian-cancer guide covers symptoms, CA-125, imaging and specialist evaluation.
Use a named screening guideline
For U.S. people with a cervix at average risk, the American Cancer Society guideline, updated in 2025, starts routine screening at age 25 and continues through at least 65, with the stopping decision dependent on prior results and risk. Its options after a negative routine screen are summarized below.
On a small screen, scroll the table sideways. Keyboard users can focus the table region and use the arrow keys.
| Test and collection | Usual interval | Place in the guideline |
|---|---|---|
| Clinician-collected primary HPV test | 5 years | Preferred option. |
| Self-collected vaginal HPV sample | 3 years | Acceptable with an FDA-authorized test and collection system. |
| Clinician-collected HPV/Pap co-test | 5 years | An alternative screening approach. |
| Pap test alone | 3 years | An option when HPV-based approaches are unavailable. |
These intervals do not apply to managing an abnormal result. The ACS update also revises the evidence needed to stop screening. Review actual records with the clinician before stopping; age alone is insufficient.
Organizations differ. HRSA’s women’s preventive-services guidance uses a different age framework, and NCI describes the differences among screening recommendations. Ask which guideline your service uses and why it fits you. Prior precancer or cancer, immune suppression, HIV, prenatal DES exposure or certain previous results can require another plan. After hysterectomy, whether the cervix remains and the reason for surgery matter.
Choose a collection method with a follow-up plan
Self-collection for HPV testing uses a vaginal sample. A clinician-collected cervical sample can support additional cell testing; these are different specimens. Ask the service which authorized test/device combination it offers, whether collection is permitted in the clinic or at home, and what age and medical-history requirements apply.
The FDA’s Teal Wand device record documents a May 2025 authorization for a specific home-collection system. This does not make every online HPV kit equivalent. Use the healthcare service’s ordering, collection, transport and result instructions.
If a self-collected result is positive, additional clinician-based assessment is usually needed. Before choosing the test, identify where that follow-up would happen. For an examination, tell the clinician about pain, prior difficult experiences, disability or privacy concerns. Ask for an explanation before each step and request a pause when needed.
Read the result and arrange the next step
NCI’s guide to abnormal HPV and Pap results explains terms such as ASC-US, LSIL and HSIL. These are findings that guide risk assessment; the letters by themselves are not a treatment plan. Copy the exact HPV result, any reported genotype, cytology wording, specimen date and earlier history.
Depending on the combined information, a clinician may recommend repeat testing at a defined interval, colposcopy, biopsy or treatment of a high-grade lesion. Colposcopy lets a clinician examine the cervix closely and sample areas when appropriate. Ask what the visit is intended to establish and how the findings will affect care.
An unsatisfactory specimen needs a specific repeat-testing plan. If you are pregnant, have prior treatment of cervical precancer, or take immune-suppressing medicines, make sure the team knows before the next procedure. Ask about procedure effects, pregnancy plans and aftercare when treatment is proposed.
Close the follow-up loop
- Agree on when and how results will arrive; call if that date passes.
- Record the exact next test or procedure, the responsible service and the target date.
- Ask which symptoms should prompt an earlier call.
- After a procedure, obtain the result and the next surveillance plan.
- Keep screening records when changing healthcare providers.
Download the cervical results and follow-up notes to organize these details privately.
HPV vaccination prevents new infections and related cancers; it does not clear an existing infection or replace indicated screening. If invasive cancer is diagnosed, the conversation moves to staging and treatment with a cancer-care team. For broader prevention priorities, see practical cancer risk reduction.
Updated October 9, 2026. General education for conversations with qualified health professionals; individual care depends on your history, results and local guidance.
Explore the Cancer guides and topic directory.